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Different PD-MCI criteria and risk of dementia in Parkinson’s
disease: 4-year longitudinal study
Kyla-Louise Wood1,2, Daniel J Myall2, Leslie Livingston2,3, Tracy R Melzer2,3,4, Toni L Pitcher2,3, Michael R MacAskill2,3, Gert J Geurtsen5,
Tim J Anderson2,3,4,6 and John C Dalrymple-Alford1,2,3,4
The Movement Disorder Society Task Force (MDS-TF) has proposed diagnostic criteria for mild cognitive impairment in Parkinson’s
disease (PD-MCI). We hypothesized that the risk of dementia (PDD) varies across the different cutoff schemes allowed. A
longitudinal study followed 121 non-demented PD patients for up to 4.5 years. In Part One, unique groups of patients were
identified as PD-MCI at baseline using the MDS-TF requirement of two impaired cognitive test scores, with both scores classified as
impaired at either (i) 2 s.d., (ii) 1.5 s.d. or (iii) 1 s.d. below normative data; relative risk (RR) of PDD was assessed at each criterion. In
Part Two, the whole sample was reassessed and (i) RR of PDD determined when two impairments at 1.5 s.d. existed within a single
cognitive domain, followed by (ii) RR of PDD in the unique group whose two impairments at 1.5 s.d. did not exist within a single
domain (i.e., only across two domains). Twenty-one percent of patients converted to PDD. Part One showed that the 1.5 s.d.
criterion at baseline is optimal to maximize progression to PDD over 4 years. Part Two, however, showed that the 1.5 s.d. cutoff
produced a high RR of PDD only when two impairments were identified within a single cognitive domain (7.2, 95% confidence
interval (CI) = 3.4–16.6, Po0.0001; 51% converted). The RR when the 1.5 s.d. impairments occurred only across two different
domains, was nonsignificant (1.7, CI = 0.5–7.4, P= 0.13; 11% converted) and similar to using a 1 s.d. criterion (1.9, CI = 0.3–4.3,
P= 0.13; 8% converted). If the intent of a PD-MCI diagnosis is to detect increased risk of PDD in the next 4 years, optimal criteria
should identify at least two impairments at 1.5 s.d. within a single cognitive domain.
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INTRODUCTION
In Parkinson’s disease (PD), cognitive impairment and other
non-motor symptoms have a greater impact on quality of life than
do motor symptoms and are associated with early mortality.1,2
Some 60% of patients may develop dementia (PDD) within
12 years of their motor symptoms and over 80% ultimately reach
PDD, although an individual’s time course to dementia is highly
variable.3–5 Risk factors include older age and severity of motor
symptoms, but recognition of early cognitive impairment is
particularly important.6–10 Recently, studies have examined the
progression to PDD from mild cognitive impairment (PD-MCI).
Although specific findings are variable, more PD-MCI patients than
non-PD-MCI patients progress to PDD (19–62% vs. 0–20%,
respectively) when followed 2 to 5 years after showing
PD-MCI.11–13 In a cohort that was followed for 16 years, 91% of
PD-MCI patients reached PDD, over four times that of the
non-PD-MCI patients.14 It is difficult to compare these studies,
however, as each used different diagnostic criteria to define PD-MCI.
The heterogeneous methods to ascertain PD-MCI has led to
substantial variation in the percentage of patients classified as
PD-MCI.11,15–18 To address this situation, standardized diagnostic
criteria were proposed by the Movement Disorder Society PD-MCI
Task Force (MDS-TF).19 The Task Force’s Level I criteria permit the
use of global cognition scales or an abbreviated neuropsycholo-
gical assessment that includes fewer than two tests in each of
five cognitive domains (attention/working memory; executive
function; episodic memory; visuoperceptual/visuospatial function;
language) or when fewer than five cognitive domains are
assessed. More specific, comprehensive (Level II) criteria require
the use of more than one test in each of the cognitive domains
and PD-MCI is confirmed when any two (or more) impaired
neuropsychological test scores are present but everyday function
is generally preserved. Nonetheless, the Level II recommendations
still permit several alternative criteria, for example, cutoffs ranging
1–2 s.d. below normative data to define an impaired score.19
We hypothesized that the risk of progression to PDD differs
across three common cutoff variants for PD-MCI (1, 1.5 and 2 s.d.)
permitted by the MDS-TF recommendations. Moreover, the high
probability of eventual PDD for all patients means that the validity
of PD-MCI criteria should be determined by whether they detect
patients at increased risk of PDD within a defined period of time.
Here, we specified a 4-year window as a suitable period of time
because we considered this relevant for the use of PD-MCI in both
clinical practice and potential therapeutic interventions.20 There is,
however, a second important issue that has also not been
addressed: does the distribution of impaired scores across
domains influence the risk of conversion to dementia? On the
basis of evidence from the non-PD literature on MCI,21,22 we
hypothesized that having a minimum of two impaired test scores
within a single cognitive domain would result in a higher risk of
PDD compared with having a minimum of two impaired test
scores spread across different cognitive domains.
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RESULTS
Participants
The mean patient age at baseline was 66 years (s.d. = 8 years).
Table 1 summarizes the demographics and neuropsychological
data of the patients and healthy control group at baseline. There
was a 21% conversion rate to dementia for the PD patients in the
4-year period (14 men and 11 women; 25 out of 121 patients). As
expected, patients who later converted to PDD were older, had
longer symptom duration and worse motor symptoms, neurop-
sychological and functional measures at baseline than patients
who did not convert to PDD. At baseline, 26 out of the 121 non-
demented patients experienced hallucinations. A greater propor-
tion of converters (13 vs. 12; 52%) relative to non-converters
(13 vs. 83; 14%) experienced hallucinations at baseline
(chi-square = 17.39, Po0.0001; Table 1). Fifteen of the 25 patients
(60%) who converted to PDD experienced hallucinations at the
time of conversion, whereas only 24 of the 96 non-converters
experienced hallucination at their last assessment (chi-square =
11.12, Po0.001). Relatively few patients (9 out of 121) received
medication that may affect their cognitive performance during the
study. At baseline, only one patient who did not convert to PDD at
follow-up was on antipsychotic medication and one that did
convert to PDD was receiving rivastigmine. Neither of these
patients remained on these medications at their follow-up
assessments. At follow-up, seven patients were on medication
that could affect their cognition. Six of these seven patients were
on antipsychotic medication (three of whom had progressed to
PDD), and three were receiving donepezil (one of whom had
progressed to PDD).
Part one: comparison of progression to PDD from PD-MCI defined
by three cutoffs
Risk of PDD. The first stage of analysis showed that the 46
patients classified as PD-MCI using the 2 s.d. cutoff had a
significantly higher risk of progression to PDD than the
remaining 75 PD patients (relative risk, RR = 4.2, confidence
interval (CI) = 2.2–10.1, Po0.0001; Table 2). A similar finding was
evident in the 10 patients missed by the 2 s.d. classification but
defined as PD-MCI using the 1.5 s.d. cutoff (RR = 4.9, CI = 1.4–15.1,
P= 0.005). By contrast, the additional group of 40 patients
classified as PD-MCI using the 1 s.d. cutoff criterion did not show
a significantly greater risk of PDD progression than the remaining
25 patients not classified as PD-MCI under any of these three initial
criteria (RR = 1.9, CI = 0.3–4.3, P= 0.13).
Reversions from PD-MCI. Under each criterion, there were
individuals who at their latest follow-up were classified as
reverting to a non-PD-MCI status (i.e., to relatively ‘normal’
cognition under that criterion). For the 2 s.d. cutoff, 20% (9/46)
of patients had reverted to a non-PD-MCI status at their last
assessment (i.e., no longer having two impairments below 2 s.d.).
Of these nine reverters, seven had scores that also remained
below a 1.5 s.d. cutoff, but no longer met the 2 s.d. cutoff. There
was just one reversion in the extra 10 patients identified as
PD-MCI under the 1.5 s.d. criterion (i.e., in the group whose
baseline scores reached the 1.5 s.d. cutoff but not the 2 s.d. cutoff).
The reversion rate in the group of patients who met only the 1 s.d.
criterion was 20% (8/40).
Healthy control group. Unlike the PD sample, none of the
matched control group converted to dementia during the
follow-up period. Only one control participant met the 2 s.d.
criterion at baseline (showing one impairment within each of the
two domains), two met the 1.5 s.d. criterion (each showing one
impairment within each of the two domains) and 12 met the 1 s.d.
criterion for MCI. By the end of the 4-year follow-up, however, the
first control was no longer classified as MCI under the 2 s.d.
criterion (having one impairment within each of the two domains,
but now at 1.5 s.d.), while the two who had met the 1.5 s.d.
Table 1. Demographics and neuropsychological data at study entry (mean (s.d.))
Controls Non-converters to PDD Converted to PDD
Sample size 36 96 25
Sex, M:F 25:11 63:33 14:11
Age 67.5 (8.6) 64.3 (8.2) 70.2 (5.7)a
Symptom duration (y) 5.3 (4.0) 7.8 (5.0)a
Hoehn and Yahr stage 1.9 (0.6) 2.5 (0.7)a
UPDRS (motor) 31.4 (16.2) 40.7 (15.4)a
Patients with hallucinations 13 13b
Education (y) 13.7 (2.7) 13.1 (2.7) 12.5 (2.8)
Premorbid IQ (WTAR) 112 (10.0) 111 (8.0) 109 (8.2)
CDR 0.0 (0.0) 0.2 (0.2)c 0.5 (0.2)a,c
Reisberg IADL 0.2 (0.2) 0.4 (0.4) 1.1 (0.6)a,c
DRS-2 (AESS) 12.8 (2.1) 11.7 (2.0) 10.7 (2.1)c
ADAS-Cog 5.1 (2.1) 6.6 (2.9) 10.0 (2.5)c
MoCA 26.9 (2.0) 26.1 (2.5) 23.6 (2.5)a,c
Global Z score 0.64 (0.42) 0.06 (0.53)c − 0.81 (0.47)a,c
1. Executive function 0.73 (0.56) 0.12 (0.71)c − 0.81 (0.64)a,c
2. Attention, working memory & processing speed 0.37 (0.55) − 0.06 (0.55)c − 0.77 (0.51)a,c
3. Episodic memory 0.95 (0.81) 0.06 (0.88)c − 1.05 (0.69)a,c
4. Visuoperceptual/ visuospatial 0.52 (0.51) 0.11 (0.60)c − 0.62 (0.67)a,c
5. Languaged − 0.07 (0.44) 0.12 (0.45) −0.36 (0.50)a
Abbreviations: ADAS-Cog, Alzheimer’s dementia assessment scale-cognitive; CDR, clinical dementia rating; DRS-2 (AESS), dementia rating scale-2 (age and
education scaled score); Global Z score, mean derived from domains 1–4; IADL, instrumental activities of daily living; MoCA, Montreal Cognitive Assessment;
PDD, patients who met Level II criteria for Parkinson disease with dementia; UPDRS (Motor), Unified Parkinson’s disease rating scale (motor component);
WTAR=Wechsler test of adult reading for premorbid IQ; 1–5, mean Z scores in each cognitive domain.
aSignificantly different from PD non-converters, Tukey post hoc tests, Po0.05.
bSignificantly different proportion than PD non-converters, chi-square, P= 0.0001.
cSignificantly different to controls, Tukey post hoc tests, Po0.05.
dEight controls and 37 PD patients did not have language measures at baseline.
Cognitive impairment criteria and dementia risk
K-L Wood et al
2
npj Parkinson's Disease (2016) 15027 © 2016 Parkinson's Disease Foundation/Macmillan Publishers Limited
criterion and six of those who had met the 1 s.d. criterion no
longer met any MCI criterion.
Part two: influence of the distribution of impaired scores within or
across domains
The analysis in Part One led us to select the 1.5 s.d. cutoff as optimal
for the second phase of analysis. The reason for this selection was
that (i) the 1 s.d. criterion failed to identify an increased risk of
progression to PDD, (ii) a similar RR of conversion to PDD was found
for both the 2 s.d. and 1.5 s.d. criteria, (iii) the reversion rate was
lower in the 1.5 s.d. criterion and (iv) combining the 2 s.d. and 1.5 s.d.
groups captured a greater percent of converters to PDD. We
therefore re-examined the entire sample of followed patients to
look at the influence of the distribution of impaired scores at
baseline (that is, using all the patients meeting a 1.5 s.d. criterion,
including those meeting a 2 s.d. cutoff at baseline). The focus here
was first to determine the relative risk of PDD when two (or more)
impairments at 1.5 s.d. were present within a single cognitive
domain. We then examined risk when only a single impairment at
1.5 s.d. was evident across at least two cognitive domains (that is,
never two impairments within any one domain, but rather just one
impairment at 1.5 s.d. in each of two or more domains). Of course,
all of the PD-MCI patients classified using the 2 s.d. criterion by
definition also met one of these 1.5 s.d. criteria.
PD-MCI at 1.5 s.d. with two impairments within a single domain.
The group of 37 patients classified as PD-MCI at baseline using the
criterion of two impairments at 1.5 s.d. in one cognitive domain (of
whom 51% converted to PDD), had a high relative risk of
progression to PDD compared with 84 patients (of whom 7%
converted to PDD) who did not meet this criterion (RR=7.2, CI = 3.4–
16.6, Po0.0001; Table 2; 76% of all conversions to PDD). This risk
was not influenced solely by the subgroup of patients (n=26; 54%
converted to PDD) who showed two impairments at 2 s.d. within a
single domain (RR=4.7, CI = 2.4–8.7, Po0.0001), because the
relative risk of the remaining subgroup of patients (n=11; 45%
converted to PDD) with two impairments at 1.5 s.d. (but not 2 s.d.) in
one domain was also high (RR=6.4, CI = 2.2–15.6, P=0.0001).
PD-MCI at 1.5 s.d. with a maximum of one impairment in each of
two domains. The additional group of 19 patients classified as
PD-MCI using the criterion of only one impairment at 1.5 s.d. in
each of two (or more) domains (of whom 11% converted to PDD)
did not show a significantly increased risk of progressing to PDD
compared with the remainder of PD patients (RR = 1.7, CI = 0.5–7.4,
P= 0.13).
Reversions from PD-MCI at 1.5 s.d. The proportion of patients
reverting to a non-PD-MCI status was only 3% with the 1.5 s.d.
criterion of two impairments in a single-domain, but was 16% with
the 1.5 s.d. criterion of one impairment in two domains. Combined
across these two 1.5 s.d. criteria, the reversion rate was 5% (that is,
including scores below either the 2 s.d. or 1.5 s.d. cutoff; 3 of 56
patients).
Progression over time and pattern of domain impairments.
Support for the conclusion that two impairments within a single
domain was effective in identifying PD-MCI patients at risk of PDD
over a 4-year period was found when the progression of cognitive
status was assessed in three groups of patients that were
characterized differently at baseline using 1.5 s.d. criteria. More
than half of the patients who did not meet either of the 1.5 s.d.
criteria at baseline remained non-PD-MCI over the 4-year period
(Figure 1a). It is pertinent that patients who met the PD-MCI
criterion (at baseline) of a maximum of one impairment in each of
two domains tended to progress to meet the alternative PD-MCI
criterion of two impairments in one domain, rather than to PDD
(Figure 1b). In contrast, those who met the PD-MCI criterion (at
baseline) of two impairments in one domain tended either to
remain stable at this criterion or progress to PDD (Figure 1c).
Figure 2 shows the pattern of domain impairments at baseline
in the PD-MCI group who had at least two impairments at 1.5 s.d.
within at least one of the five cognitive domains. Note that
multiple-domain impairments therefore meant that they had two
impairments in each domain of two or more domains. Most of
these PD-MCI patients (25 of 37) had multiple-domain impair-
ments (thus defined). Sixty-four percent of the patients with
multiple-domain impairments converted to PDD (16 of 19),
whereas only 25% of those with single-domain impairments (3
of 12) converted to PDD. All PD-MCI patients who had multiple-
domain impairments that included memory, irrespective of
conversion or not, had a mixture of other domains involved
(memory and executive, n= 5; memory and visuospatial, n= 3;
memory, executive and attention, n= 4; memory, executive and
visuospatial, n= 1; memory, executive, attention and visuospatial,
n= 1). Multiple-domain impairments that did not include memory
were: executive and attention, n= 5; executive and visuospatial,
Table 2. Conversion to PDD and reversion to non-PD-MCI status
Criteria Three primary PD-MCI criteria Two alternative 1.5 s.d. PD-MCI criteria
2 s.d. 1.5 s.d. 1 s.d. 2 in 1 domain 1 in each of 2 domains
PD-MCI (n/remaining sample) 46/121 10/75a 40/65b 37/121c 19/84d
Relative risk (95% CI)e 4.2 (2.2–10.1) 4.9 (1.4–15.1)a 1.9 (0.3–4.3)b 7.2 (3.4–16.6)c 1.7 (0.5–7.4)d
PDD conversions from PD-MCI group 18/46 (39%) 3/10 (30%)a 3/40 (8%)b 19/37 (51%)c 2/19 (11%)d
Proportion of all PDD conversions 18/25 (72%) 3/25 (12%)a 3/25 (12%)b 19/25 (76%)c 2/25 (8%)d
Sex of PDD converters (M:F) 10:8 2:1a 1:2b 10:9c 2:0d
Reverted to non-PD-MCIf 9/46 (20%) 1/10 (10%)a 8/40 (20%)b 1/37 (3%)c 3/19 (16%)d
Abbreviations: 95% CI, confidence interval of relative risk; non-PD-MCI, patients not meeting the PD-MCI criterion; PDD, Parkinson’s disease patients who met
level II criteria for Parkinson’s disease with dementia at follow-up; PD-MCI, Parkinson’s disease patients with mild cognitive impairment at baseline.
aAdditional PD-MCI patients captured by the 1.5 s.d. cutoff score, excluding the 46 who had already met the more stringent 2 s.d. cutoff.
bAdditional PD-MCI patients captured by the 1 s.d. cutoff score, excluding the 56 who had already met the more stringent 2 s.d. and 1.5 s.d. cutoffs.
cPD-MCI patients, within the whole sample of 121 at baseline, who met the criterion of having two impairments at 1.5 s.d. within a single domain.
dAdditional PD-MCI patients captured by this cutoff score excluding those who had already met the two impairments in one-domain criterion.
eIncidence rate in PD-MCI group divided by the incidence rate in the non-PD-MCI group, which is statistically significant when the lower bound of the CI is
greater than 1.
fThe number of PD patients reverting back to normal cognition rather than remaining PD-MCI or progressing to PDD, according to the PD-MCI cutoff criterion
being examined.
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n= 3; and attention and visuospatial, n=3. No PD-MCI patients had
single-domain impairments in visuospatial function or language.
There was no obvious pattern to the domains impaired and
conversion to PDD.
DISCUSSION
The diagnosis of PD-MCI is important in facilitating patient
management, prognosis and especially opportunities for novel
therapeutic interventions.8–10,19,20 The explicit intent of a PD-MCI
diagnosis is to identify patients who are at risk of PDD, and this
can only be determined by longitudinal follow-up of patients.
Dementia is an outcome facing most PD patients as the disease
unfolds and multiple brain networks become increasingly
disrupted.23–26 The validity of a PD-MCI diagnosis is therefore
most relevant in the context of the window of time when risk is
evaluated. Our longitudinal study evaluated this risk over a 4-year
period, a pertinent medium-term time-frame from the patient and
their carer’s perspective.
In a typical age group of patients (42 to 80 years, mean of 66
years; mean disease duration of 6 years at the start of the study),
we found that the 1 s.d. cutoff did not identify patients who were
at higher risk of PDD over the next 4 years than patients who did
not meet any PD-MCI criterion at baseline. By contrast, the
criterion of impairments at 1.5 s.d. below normative data, when at
least two such deficits occurred within one cognitive domain, has
high validity for PDD risk in a 4-year period. This criterion classified
a group with a 51% progression rate to PDD, the highest
proportion of conversions for the criteria we examined. The
literature on MCI in non-PD populations has established that poor
performance on multiple tests within a domain is likely to identify
worsening cognition over time.21,22 The alternative 1.5 s.d.
criterion, which did not require two impairments within a single
domain, was similar to the 1 s.d. criterion in that it did not identify
patients with a significantly increased risk of PDD progression over
a 4-year period. Indeed, this alternative 1.5 s.d. criterion instead
may identify patients who were at an earlier stage of cognitive
decline because many of these patients were more likely to
convert to having two impairments within a single domain than to
PDD. The option of 2 s.d. as a cutoff criterion has good concordance
with a consensus clinical diagnosis of PD-MCI when neuropsycho-
logical data are available for assessment.18 However, the 2 s.d.
criterion applied to our sample produced a lower relative risk
estimate because it missed the additional conversions to PDD
captured by the 1.5 s.d. cutoff, especially when two impairments
occurred within one cognitive domain. The 2 s.d. criterion also
produced an apparent higher rate of reversion to a non-PD-MCI
status at follow-up than did the specific 1.5 s.d. criterion requiring
two impaired scores within a single domain (20% vs. 3%,
respectively). A recent proposal suggested the use of 2 s.d. cutoffs
for PD-MCI criteria,18,27 but that study used a cross-sectional design
and thus did not assess progression over time to PDD. The
longitudinal design of the present study suggests instead that a
1.5 s.d. cutoff is sufficient to maximize the risk of progression to PDD.
PD-MCI criteria using different cutoff values result in a
percentage of patients classified as impaired at a given point in
time that can vary from as high as 92% to as low as 10%.15–18 The
current consensus based on non-standardized PD-MCI criteria is
that 25–30% of PD patients at any given time will demonstrate
PD-MCI when the most common cutoff of 1.5 s.d. is administered,
but even then significant variation is found across centers.15
Similarly, within our study, 46% of patients at baseline were
PD-MCI when a 1.5 s.d. cutoff with only a single impairment in
each of two cognitive domains was applied across the entire
sample, but 31% were PD-MCI when the minimum of two
impairments within a single domain was met. The proportions
differed again if the entire sample was evaluated using 2 s.d. or
1 s.d. cutoffs (38% and 79%, respectively). Hence, different
permissible MDS-TF cutoffs (1, 1.5 or 2 s.d.) contribute to
considerable variation in the proportion of PD-MCI identified
within a given sample of patients. More importantly, our 4-year
study illustrates that different cutoff variants identify groups of
patients with markedly different relative risks of progression to
PDD, and different rates of reversion to non-PD-MCI.
Several factors could influence conversion or not to PDD within
any group of patients. The small proportion of PD patients who do
not progress to PDD until very old age may be protected by
genetics and/or lifestyle factors that confer resilience to brain
pathology.28,29 Some patients may be misdiagnosed as PD-MCI
because either their depleted dopaminergic function or their
treatment regimens may induce various fronto-striatal dysfunc-
tions that cause cognitive impairment that does not necessarily
portend progression to PDD.30 There are also contributions to risk
from general factors such as age, presence of REM sleep disorder
and additional neuropathology.6,7,24,31,32 In some patients, the
extent of decline from premorbid level of intellectual function may
be more relevant than rigid cutoffs.33 Hence, consideration of age
or other variables may improve the predictive value of the specific
criterion suggested by our study. Like other studies of conversion
to PDD from PD-MCI, we found similar rates of conversion to PDD
Figure 1. Follow-up cognitive status in the non-PD-MCI group at
baseline (a) and the PD-MCI subgroups meeting the criterion of
one impairment at 1.5 s.d. in each of two domains (b) and the
criterion of two impairments at 1.5 s.d. in one domain (c). aOriginal
criterion at baseline. non-PD-MCI, patients not meeting the PD-MCI
criterion; PD-MCI, Parkinson’s disease patients with mild cognitive
impairment.
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between the sexes when the 1.5 s.d. criterion was used (10 men
and 9 women).11,12
The pattern of cognitive domain impairments observed in the
patients who met the criterion of two impairments at 1.5 s.d. in a
single domain showed no obvious association with conversion to
PDD, which is consistent with the heterogeneity of failing
cognition in PD.11,13,34–36 Like other studies, multiple-domain
impairments may be more common in PD-MCI18 and more likely
to be associated with conversion to dementia.13 The frequency of
multiple-domain impairments will vary, however, with the specific
PD-MCI criteria that are applied. In some studies, most PD-MCI
patients showed multiple impairments, often as high as four
domains impaired, when only a single impairment per domain was
required.18,33 The present study had only one patient with four
impaired domains, when using two impairments necessary for any
domain to be considered deficient. Multiple deficit scores within a
single domain, however, appears to be optimal to identify
conversion to PDD within 4.5 years. Neither the language nor
visuospatial domains showed single impairments using our criteria,
so it is possible that worsening attention, executive function and
memory may reflect the earlier signs of global cognitive decline in
PD, similar to that reported by Pedersen et al.12
The strength of the current study is its longitudinal design and
the use of Level II assessments for both PD-MCI and PDD
diagnoses. It evaluated for the first time the validity of different
recommended PD-MCI criteria in relation to PDD progression. The
use of a specified medium-term window for progression is highly
relevant because the high rate of eventual progression PDD
means that virtually all PD-MCI criteria will identify conversion to
PDD if the follow-up period is sufficiently long. The 4-year window
is particularly relevant for patients and their families, as it meets
their expectations for clinical management while also allowing for
the assessment of potential therapeutic outcomes.
One limitation to our study, like similar studies, is that the
sample size was modest (n= 121) and there was potential for bias
owing to an attrition rate of 18%. Our sample size was twice that
of three studies that examined PDD progression over 3–5 years
(n= 51–64),11,13,14 but smaller than one study that followed
patients over 3 years (n= 167).12 Our attrition rate (18%) was half
that of two of these studies (41 and 48%),13,14 equivalent to one
study (18%)11 and larger than another (8%).12 The current data
will, however, contribute to an international consortium to enable
better statistical precision for determining relative risk of PDD
from different cutoff options, and the ability to assess the
influence of potential modifiers such as age and education.37
A second limitation is that the identification of PD-MCI may
depend on the number of tests we used per domain, and
especially the sensitivity and psychometric qualities of our
individual tests. The uneven number of tests per domain in our
study could mean that the attention and executive functioning
domains, each of which consisted of six tests, may be more likely
to detect impairment than, say, the visuospatial domain for which
four tests were used. However, Goldman et al.27 found that having
more than two tests in the attention and/or executive function
domains did not increase the probability of detecting an
impairment and that having more tests in memory, visuospatial
functioning and language only increased by 5% the chance of
finding more domain impairments. In terms of the sensitivity of
tests, there is mixed evidence whether ‘frontal’ or ‘posterior’
cortical tests provide good predictors of decline to PDD.11,30,34–36
Indeed, the allocation of tests to cognitive domains may also differ
across experts because tests vary in their domain purity. This issue
is relevant to the current findings in which multiple impairments
within a domain better identified those PD-MCI patients at risk of
conversion to PDD, at least over a 4-year period. For example,
executive function tests can vary in their domain allocation12,18
and visuospatial tests range from specific measures through to
more complex tasks that also involve orientation, attention,
memory and executive function.38 That is, the selection of tests
and their domain purity may contribute to variation in the
frequency of impairments reported across studies. These limita-
tions emphasize the need for further evaluation of cognitive
impairments and progression to PDD.
The conclusion from the current study is to adopt a specific
PD-MCI criterion when the intent is to identify a medium-term
(up to 4 years) risk of progression to PDD. For this purpose, the
requirement of at least two deficits at 1.5 s.d. below normative
data within any single cognitive domain provides a valid PD-MCI
diagnosis that optimizes the relative risk of progression to
dementia. Deciding upon the selection and number of tests




A convenience sample of 184 PD patients was recruited from our research
institute and movement disorders clinic. Comparison of the rate of
progression to PDD in this sample was made by recruiting 54 age-,
sex- and education-similar healthy controls who volunteered in response
to community advertisements and did not report subjective cognitive
complaints. Figure 3 shows recruitment, exclusions and retention of
participants,39 which resulted in a final followed-up sample of 121 PD
patients, none of whom met PDD criteria40 at baseline, and 36 controls.
Patients were diagnosed using the UK Parkinson’s Society criteria41
and had motor symptoms present for at least 1 year at study entry
Figure 2. Pattern of domain impairments at baseline in PD patients meeting the criterion of at least two impairments at 1.5 s.d. in one domain.
PDD, patients who met level II criteria for Parkinson’s disease with dementia; PD-MCI, Parkinson’s disease patients with mild cognitive
impairment.
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(mean symptom duration= 6 years, s.d. = 4 years) to minimize the inclusion
of those with dementia with Lewy bodies. Atypical parkinsonian disorder,
other medical conditions (e.g., history of moderate/severe head injury,
stroke, early-life learning disability, major psychiatric or medical illness in
the previous 6 months), poor English (precluding testing) were the
exclusion criteria. Patients were also excluded at baseline if they had
Parkinson’s disease with dementia.40 A PDD diagnosis at any point in the
study required the presence of significant impairments (2 s.d. below
normative data) in at least two of five cognitive domains, plus evidence of
significant impairment in everyday functional activities, not attributed to
motor impairments. Everyday function was assessed from interviews with a
significant other, based on evidence obtained from the Reisberg
IADL-scale, Clinical Dementia Rating and Global Deterioration Scale to
attribute non-dementia status or PDD.42,43 Direct evidence from a
significant other was not available, at baseline only, in 39 PD patients.
However, we confirmed baseline non-dementia status in these cases from
contemporaneous clinical notes and from detailed patient interview by an
experienced examiner, followed by consensus discussion.
Comprehensive neuropsychological assessments fulfilling the MDS-TF
Level II requirements for PD-MCI (for tests see below)19 were undertaken at
study entry and subsequently every 1 to 2 years, for up to 3.5–4.5 years later
(mean=46 months, s.d. = 8 months). Progression to PDD before the end of
the 4.5-year period was treated as an a priori end point, with no further
follow-up. All the participants took their usual medications on the day of
testing to allow optimal performance during the morning test sessions. The
study was approved by a local ethics committee of the New Zealand
Ministry of Health, with informed consent provided by all the participants.
Neuropsychological assessment
Five cognitive domains were examined, with tests conducted over two
sessions.16,38,44 Executive function was assessed using Stroop interference,
letter fluency, category fluency and category switching (from the
Delis-Kaplan Executive Function System45), and action fluency and Trails
B. Attention, working memory and processing speed was evaluated using
digits forwards/backwards, digit ordering, map search task (from the test of
everyday attention), Stroop color reading, Stroop word reading and Trails
A. Episodic memory was measured with the California Verbal Language
Test-II Short Form (acquisition, short and long delays), and the Rey
Complex Figure Test (short and long delays); impairment in either or both
delay components of each memory test counted as one impairment.
Visuoperceptual/visuospatial performance was determined using judg-
ment of line orientation, fragmented letters test, the picture completion
test and the Rey Complex Figure Test-Copy. Language was assessed using
the Boston Naming Test, Dementia Rating Scale-2 similarities sub-test, and
the language component of the Alzheimer’s Dementia Assessment
Cognitive Scale (object and finger naming, commands, comprehension,
spoken language and word-finding difficulties). Scoring of the neuropsy-
chological tests was conducted using age- and education-adjusted
normative data. Participants also completed the Montreal Cognitive
Assessment.
Application of PD-MCI criteria
There were two phases to the analysis. In Part One, we applied three
commonly used and accepted PD-MCI cutoff criteria to examine their
association with risk of progression to PDD, irrespective of whether the
minimum of two impairments occurred within a cognitive domain or across
different cognitive domains. In Part Two, we examined the additional issue of
the distribution of impairments across domains, focusing on the optimal cutoff
criterion resulting from the analysis in Part One. That is, we again determined
risk of progression with a minimum requirement of two impairments, but first
with both impairments within a single cognitive domain and then when there
was only one impairment in each of two or more domains.
Part one. To test the unique contribution of each PD-MCI criterion, we
generated three mutually exclusive groups of PD-MCI patients using a
stepwise process. The three primary s.d. cutoff scores were applied
Figure 3. Participant recruitment, exclusions and total followed over 4 years. aAssessments were conducted at baseline and every 1 to 2 years;
patients with dementia were not followed further. MRI, magnetic resonance imaging; PD, Parkinson’s disease; PDD, Parkinson’s disease with
dementia.
Cognitive impairment criteria and dementia risk
K-L Wood et al
6
npj Parkinson's Disease (2016) 15027 © 2016 Parkinson's Disease Foundation/Macmillan Publishers Limited
sequentially to signify impairment on any test measure (Figure 4, Part
One). First, we identified patients who had two scores that were 2 s.d. or
more below normative data, then from the remainder we identified those
with two scores that were 1.5 s.d. but better than 2 s.d. below normative
data, and last those with two scores that were 1 s.d. but better than 1.5 s.d.
below normative data. Thus each PD-MCI group in Part One consisted of
an independent and discrete sample of patients for analysis purposes. In
clinical practice, any patient who met a 2 s.d. criterion would also by
definition meet the 1.5 s.d. or 1 s.d. criterion (and similarly those meeting
1.5 s.d. also exceed the 1 s.d. criterion). It is important for the purpose of
comparing the effectiveness of the cutoffs, however, that groups of
patients classified under each criterion be mutually exclusive. For example,
the effectiveness of the 1.5 s.d. criterion cannot be meaningfully compared
with the 2 s.d. criterion if both capture overlapping groups of subjects.
Thus, once a patient was identified as PD-MCI (for example, under the 2 s.d.
criterion), they were excluded from the next step in the analysis so that
effectiveness of a criterion was not influenced by the more severely
impaired patients who would also be captured by a more stringent
criterion. That is, we began by applying the 2 s.d. criterion at baseline to all
of the 121 non-dementing patients. The risk of progression to PDD was
evaluated in this PD-MCI group relative to the remainder of the PD
patients. This 2 s.d. PD-MCI group was then excluded and, using only the
remaining patients, the risk of PDD was assessed in patients who met the
1.5 s.d. PD-MCI cutoff relative to those not meeting the 1.5 s.d. criterion.
This 1.5 s.d. PD-MCI group was in turn also excluded and the remaining
sample reassessed. This final sample was used to assess the risk of PDD in
patients now meeting only the 1s.d. cutoff relative to the risk in the
remaining patients who did not meet any of the PD-MCI criteria at
baseline. Following the MDS-TF recommendations, the minimum of two
impairments at the cutoff required for any given criterion could appear
anywhere within, or across, the five cognitive domains assessed.
Part two. The second part of the analysis was different in that it examined
the influence of whether the minimum of two impaired scores occurred
either within one cognitive domain or across two different cognitive
domains. Impairments beyond two deficits did not change these
allocations. This approach was used only for the optimal cutoff score
(1.5 s.d.), as determined by Part One (Figure 4, Part Two). Here, we once
more began with the entire followed-up sample and again followed a
stepwise approach so that each PD-MCI group consisted of a discrete
(independent) sample of patients. We first identified all patients with a
minimum of two impairments at 1.5 s.d. within a single cognitive domain
at baseline (that is, all patients from the entire sample of 121 patients who
had two or more scores at or worse than the 1.5 s.d. cutoff score) and
determined the risk of dementia within this group of PD-MCI patients
relative to those who did not meet this criterion. Those meeting that
criterion were then discarded. The remaining patients were then assessed
by comparing risk in those patients who had the minimum of two
impairments at the cutoff score of 1.5 s.d. but the two impairments never
occurred within a single domain (i.e., at least two domains each having a
maximum of one impaired score) relative to the remaining patients who
did not meet either of these two PD-MCI criteria. As any patient with
multiple impairments within a single domain had been excluded in the
previous stage, then by definition this latter PD-MCI group had only one
impaired score within any one domain. In clinical practice, this second
more relaxed 1.5 s.d. criterion would also capture those with multiple
impairments within a domain, but for analysis purposes we kept the
samples independent.
Statistical analysis
Confidence intervals for relative risk of PDD in each comparison were
determined using bootstrap methods.46 In this procedure, statistical
samples were generated by resampling with replacement from the parent
sample under study and a relative risk calculated. This resampling was
repeated 5,000 times, resulting in an empirical distribution for the relative
risk for the comparison in question. Permutation tests were used to derive
exact P values. The code and data used in this analysis are available upon
request.
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